{"entity":{"id":"nct07431827","kind":"trial","name":"MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)","aka":["KANDLELIT-013"],"tldr":"A phase 3 trial testing Calderasib in non-small-cell lung cancer, now recruiting.","summary":"MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) is a phase 3 interventional study registered as NCT07431827, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 3, Randomised, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Adjuvant Placebo Plus MK-3475A in Participants With Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer Following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013). Planned enrolment is 400 participants (estimated). The study started in 2026-03-18 and primary completion is expected in 2039-10-26. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07431827","url":"https://clinicaltrials.gov/study/NCT07431827"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","kras-g12c-nsclc","resectable-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["calderasib"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07431827","phase":"3","setting":"A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Adjuvant Placebo Plus MK-3475A in Participants With Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer Following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)","sponsor":"Merck Sharp & Dohme","started":"2026-03-18","startedType":"actual","enrolled":400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07431827/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"drug":[{"id":"calderasib","kind":"drug","name":"Calderasib","route":"/drugs/calderasib/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}